A pooled analysis of 564 patients with acute ischemic stroke found that higher plasma homocysteine levels were independently associated with post-stroke cognitive impairment. The study, published in Frontiers in Nutrition, merged data from two independent cohorts to examine whether this specific biomarker could predict cognitive decline in the months following a stroke. The researchers defined post-stroke cognitive impairment as a Montreal Cognitive Assessment score of 23 or lower, measured between three and six months after the initial event. This observational study aimed to clarify the relationship between homocysteine concentrations and long-term cognitive outcomes in a large, combined patient population.
Post-stroke cognitive impairment affects approximately one-third of stroke survivors, yet early biomarkers to identify those at risk remain limited. The research team tested whether plasma homocysteine could serve as an independent predictor of this condition. The primary outcome was the presence of cognitive impairment at the follow-up assessment, with homocysteine levels serving as the key exposure variable in the statistical models.
In the combined group of 564 patients, 36.9% developed post-stroke cognitive impairment. Patients who experienced cognitive decline had significantly higher average homocysteine levels compared to those who did not, with a mean of 21.99 micromoles per liter versus 15.87 micromoles per liter. This difference was statistically significant, with a p-value of less than 0.001. The results suggest a clear distinction in biomarker levels between patients who maintained cognitive function and those who suffered measurable decline in the months following their stroke.
After adjusting for potential confounding factors using multivariable logistic regression, the association between homocysteine and cognitive impairment remained significant. The odds ratio was 1.019 for each micromole per liter increase in homocysteine, with a 95% confidence interval ranging from 1.002 to 1.037.
The relationship between homocysteine levels and cognitive impairment was not linear, as indicated by restricted cubic spline analysis. The analysis identified a threshold near 10 μmol/L, with an odds ratio of 5.32.
Combining homocysteine with other biomarkers, including Lp-PLA2, the National Institutes of Health Stroke Scale score, and beta-2-microglobulin, improved the model’s ability to discriminate between patients with and without cognitive impairment. The area under the curve for this combined model was 0.748. A mediation analysis found that the National Institutes of Health Stroke Scale score mediated 24.8% of the effect.
Dedicated clinical trials are necessary to determine whether lowering homocysteine levels can actually prevent post-stroke cognitive impairment.
Subject of Research: Association between plasma homocysteine and post-stroke cognitive impairment in ischemic stroke patients
Article Title: Association between plasma homocysteine levels and post-stroke cognitive impairment: a pooled analysis of 564 patients from two independent cohorts
Article References: Hu, L., Ni, X., Wei, M., Han, Q., & Yang, X. (2026). Association between plasma homocysteine levels and post-stroke cognitive impairment: a pooled analysis of 564 patients from two independent cohorts. Frontiers in Nutrition, 13, Article 1977295. https://doi.org/10.3389/fnut.2026.1977295
Image Credits: AI Generated
DOI: 10.3389/fnut.2026.1977295
Keywords: post-stroke cognitive impairment, plasma homocysteine, acute ischemic stroke, biomarker prediction, Montreal Cognitive Assessment, pooled analysis, logistic regression, restricted cubic spline, Lp-PLA2, beta-2-microglobulin, NIHSS, observational study, cognitive decline, stroke survivors, Frontiers in Nutrition, risk marker, meditation analysis, neurological outcomes, biomarker combination, clinical limitations
News Source: Cassandra Pierce. (November 14, 2026). Plasma Homocysteine Associated With Post-Stroke Cognitive Impairment. Scienmag.



